CFOs Are Optimistic About Their Businesses but Worried About Stock Valuations. Both Can Be Right.

Apparently, CFOs have enough confidence to grow their own businesses but would prefer not to purchase everyone else’s optimism at today’s prices.

I appreciate the distinction. It’s like believing your house is in excellent condition while wondering why the identical house down the street is listed for the price of a small airport.

Deloitte’s third-quarter 2026 CFO Signals survey offers a particularly good illustration. Ninety percent of surveyed CFOs said they were significantly or somewhat more optimistic about their own companies’ financial prospects than three months earlier. At the same time, 83% considered U.S. equity markets overvalued.

The findings come from Deloitte’s survey of large North American companies. They describe respondents’ views, not a universal consensus among every CFO or a forecast that stock prices must fall.

Still, I think the contrast is worth discussing because it gets at something Finance understands better than most: a good business and a good investment are not always the same thing.

A company can grow revenue, improve margins, generate cash and execute its strategy beautifully. Investors can still overpay for the earnings they expect it to produce.

The business can be right. The price can be wrong. Both statements can live peacefully in the same spreadsheet, although apparently not without upsetting a few valuation enthusiasts.

The interesting question for CFOs isn’t whether the survey is contradictory. It’s what they should do when their operating outlook is strong but market prices look ambitious.

First, Read the Survey Without Inventing a Contradiction

The primary source is Deloitte’s CFO Signals data dashboard. In the third quarter of 2026, its confidence score rose to 6.1 from 5.9 in the prior quarter.

Deloitte reports that 90% of respondents felt more optimistic about their own companies, while 83% said U.S. equities were overvalued, up from 49% in the second quarter.

A few details matter. The optimism question compares respondents’ current views of their companies with their views three months earlier. It does not ask whether their companies are undervalued or whether profits are guaranteed.

The market valuation question asks about U.S. equities generally. It doesn’t require a CFO to judge their own company’s stock, and it doesn’t mean every listed company is expensive.

And the two percentages should not be interpreted as proof that exactly 90% of CFOs simultaneously hold both opinions. We have two reported aggregate results, not a published cross-tabulation of individual answers.

These distinctions are not glamorous. They’re the reason Finance should read survey methodology before turning an interesting statistic into an executive presentation.

Otherwise we end up with the familiar situation where the slide is more confident than the evidence.

A Great Company Can Be a Terrible Purchase

Let’s make the difference concrete.

Imagine a business generating $100 million of sustainable annual free cash flow. For simplicity, assume that cash flow could remain flat indefinitely and that the relevant discount rate is 10%. Under a simple perpetuity calculation, the implied value is $1 billion.

Now suppose investors are willing to pay $1.5 billion for the business. That price may be justified if they reasonably expect growth, lower risk or other benefits. But it is not justified merely because management is proud of the company.

At a $1.5 billion price, the initial cash-flow yield is about 6.7%. The investor needs a story about future cash flows or discount rates to support the valuation.

Management might be absolutely correct that the company is operating well. The buyer can still earn a disappointing return if the purchase price already assumes extraordinary performance.

I see this confusion all the time in capital discussions. We fall in love with the quality of the business and forget that price is a separate variable.

A restaurant can serve an excellent dinner. That does not mean I should buy the restaurant for forty times its annual cash flow because the pasta was impressive.

The Market Pays for Expectations, Not Just Results

Stock prices reflect expectations about future cash flows, growth, risk and the returns investors demand.

That means a company can report strong earnings and see its share price fall if the results are weaker than what investors had already anticipated.

Conversely, a struggling business can see its shares rise if the results are less bad than feared or if its prospects improve.

The market is not handing out gold stars for effort. It is continuously repricing expectations.

For Finance, this means the operational plan and the investor narrative must be connected but not confused.

I want a credible view of what the business can deliver. Separately, I want to understand what the current valuation appears to require.

If the market price implies years of exceptional margin expansion, a merely good forecast may not be enough.

This is why “we beat budget” is not necessarily a compelling investor message. If the budget was conservative or the market expected even more, beating it may be an accounting victory rather than a valuation surprise.

The market does not know how many meetings it took to finalize our budget. It remains shockingly indifferent.

What Does a 30-Times Earnings Multiple Actually Require?

Suppose a hypothetical company earns $5 per share and trades at $150. Its price-to-earnings ratio is 30.

Now assume the market later values the business at 20 times earnings. If earnings remain $5 per share, the implied share price falls to $100, a decline of one-third.

What if the company grows earnings 20% to $6 per share? At 20 times earnings, the implied price is $120. Earnings have improved substantially, but the share price is still 20% below the original $150.

These examples exclude dividends and other changes. They aren’t price predictions. They’re simple demonstrations of multiple compression.

This is the part of valuation that can feel personally offensive to operating teams. They do the work. They deliver growth. The stock declines anyway.

But valuation has two moving pieces: business performance and what investors are willing to pay for that performance.

When multiples are elevated, Finance should be especially careful about plans that rely on continued market enthusiasm.

You can execute your way to better earnings. You cannot require the market to maintain the same multiple.

The CFO’s Job Is to Keep Those Two Stories Separate

I would maintain two distinct but connected conversations with management and the board.

The first is the operating conversation: what can we control, what drives returns and where can we improve cash generation?

The second is the capital-markets conversation: what do investors expect, how is risk being priced and what financing options are attractive at current valuations?

Both conversations matter, but they answer different questions.

The operating plan should not become more aggressive merely because the stock trades at a high multiple. Nor should the company abandon a profitable investment because someone believes the broad market is expensive.

I’d ask management to show the bridge between operating performance and the assumptions implied by valuation.

If our internal forecast assumes 5% growth and the market narrative seems to require 15%, we need to understand that gap.

The answer may be that our forecast is conservative, the market is looking further ahead or investors see advantages that our near-term model doesn’t capture.

It may also be that the market is optimistic. That’s allowed. Finance does not have to join in just to be polite.

Optimism Shouldn’t Turn the Budget Into Fan Fiction

When executives feel confident about their companies, the annual budget can become an exercise in proving the confidence was justified.

Sales sees a stronger pipeline. Operations expects productivity gains. Marketing promises better conversion. Technology says automation will create capacity. Everyone has a reasonable story.

Then the stories are added together as though every improvement is independent and every deadline will be met.

I like optimism when it is attached to evidence. I get nervous when it is attached to a formatting convention.

For 2027, I’d separate the base forecast from management’s stretch targets. I’d test whether expected revenue, pricing, cost and productivity improvements can all happen together.

I’ve written about this in my discussion of nervous 2027 budget assumptions. The issue is not whether leadership should be ambitious. It’s whether Finance can show what must happen for the ambition to work.

A strong company outlook should improve decision-making. It should not excuse us from testing the assumptions.

The spreadsheet will happily accept every optimistic input we give it. It has never once asked whether we’re getting carried away.

Valuation Matters Most When You Have to Make a Capital Decision

If stock valuations look rich, what should the CFO actually do?

Not necessarily anything dramatic. A market view is not a trading instruction.

But valuation can influence the relative attractiveness of issuing shares, buying back shares, acquiring businesses and financing investments.

A company considering equity issuance may find a high share price attractive because it can raise capital while issuing fewer shares. Existing shareholders still face dilution, and the decision must account for strategic needs, costs and market conditions.

A company considering buybacks faces the opposite question. Repurchasing shares at an inflated price can destroy value even when earnings per share improve mechanically.

An acquirer may find that targets are priced for extraordinary performance, making integration risk harder to justify.

A business considering debt needs to evaluate rates, covenant capacity, refinancing risk and cash-flow resilience rather than simply comparing the coupon with the expected return.

The answer depends on the specific company. But the decision framework should be consistent: value the underlying cash flows, compare alternatives and stress-test the downside.

Capital allocation is where optimism stops being a mood and becomes a check that someone has to sign.

Let’s Talk About Buybacks Without the Confetti

Share repurchases are often presented as evidence that management believes in the business.

That can be true. But conviction is not the same as valuation discipline.

Imagine a company with $200 million of excess cash and two choices. It can repurchase shares or invest in an operating project.

Suppose the project requires $200 million and has a risk-adjusted present value of $250 million. On those assumptions, the project creates $50 million of value before considering execution risks not already reflected in the analysis.

Now suppose the company’s stock trades at a price that management estimates is 25% above intrinsic value. Repurchasing at that price could transfer value away from continuing shareholders relative to buying at fair value.

The estimate of intrinsic value is uncertain, of course. That’s why I’d use ranges and scenario analysis rather than pretending Finance has discovered the one true stock price.

I’d also consider liquidity, leverage, tax effects, shareholder preferences and the possibility that management’s project forecast is too optimistic.

What I would not do is declare a buyback attractive solely because it improves EPS.

Reducing the denominator is not the same as improving the business. Mathematics is helpful, but it shouldn’t be allowed to impersonate strategy.

An Acquisition Can Be Strategically Right and Financially Wrong

High equity valuations can make acquisition math particularly entertaining.

The target has an excellent market position. The product complements ours. The management team is impressive. The presentation includes the word “synergy” seventeen times.

Then we reach the price.

Suppose a target produces $20 million in sustainable annual EBITDA and the seller wants $300 million. That’s 15 times EBITDA before transaction costs and integration spending.

Maybe the target deserves it. Maybe it has durable growth, valuable intellectual property or significant strategic benefits. But the buyer needs to underwrite those claims.

If the acquisition requires $40 million in integration costs and expected annual synergies of $15 million, I’d model the timing, probability and cost of realizing them.

I’d also ask what happens if only half the synergies appear or if the target’s growth slows.

The acquisition is not made safer because the buyer is optimistic about its own business. In fact, optimism can encourage management to overestimate its ability to integrate another company.

A strategic fit is a necessary part of many deals. It is not a substitute for a return calculation.

If it were, we’d have no need for diligence. We’d just ask whether the logos look nice together.

The Financing Mix Deserves a Fresh Look

Deloitte’s Q3 dashboard also reports that 55% of surveyed CFOs viewed equity financing as attractive, while 50% viewed debt financing as attractive.

Those are sentiment measures, not proof that either instrument is optimal for any particular company. The reported categories can also reflect different respondent views and survey definitions.

I would use them as a reminder to revisit financing assumptions rather than as a financing recommendation.

For each material investment, compare the cost of equity, after-tax cost of debt where applicable, balance-sheet capacity, covenant headroom and the resilience of cash flows under downside scenarios.

Consider a company planning a $150 million investment. If it funds the project with debt, it must service that debt regardless of whether the expected revenue arrives on time.

If it issues equity, it may avoid fixed debt service but dilute ownership. If it funds internally, it gives up cash that could support other opportunities or protect liquidity.

The right choice is not always the cheapest-looking option in the base case.

I’d test what happens if earnings fall, refinancing becomes more expensive or the project takes longer to reach cash generation.

The capital structure should survive reality, not just the board presentation.

Risk Appetite Is Not the Same as Risk Capacity

One of the most revealing Deloitte findings is that 53% of surveyed CFOs considered it a good time to take greater risks in Q3, down from 59% in Q2.

That doesn’t mean respondents expect disaster. It means enthusiasm and willingness to commit capital can move differently.

I think that’s sensible.

Risk appetite describes how much uncertainty management is willing to accept. Risk capacity describes how much the organization can absorb without jeopardizing essential obligations.

A highly profitable business with substantial cash reserves may have room to invest through a downturn. A smaller company with thin liquidity may be optimistic about demand but unable to withstand a delayed customer payment.

The Richmond Fed’s third-quarter 2026 CFO Survey highlights this difference: large firms were generally more optimistic, while smaller and financially constrained firms faced greater difficulties.

I would never approve a major risk solely because the executive team feels confident.

Confidence does not pay suppliers. Cash does.

The Liquidity Test Nobody Wants to Discuss During the Growth Presentation

Here’s a hypothetical example.

A company expects $120 million of annual revenue and $18 million of EBITDA. Management proposes a $25 million expansion funded partly with debt and partly with available cash.

The base case looks attractive. Demand grows, margins improve and the expansion pays back over time.

Now test a downside case: revenue is 8% below plan, gross margin is two percentage points lower, customers pay fifteen days later and the project requires an extra $3 million to complete.

The revenue shortfall alone is $9.6 million. At a simplified planned gross margin of 40%, that reduces gross profit by about $3.84 million before any fixed-cost response. A two-point gross-margin reduction on the lower revenue base adds roughly $2.2 million of pressure.

The collection delay can tie up additional cash, depending on sales timing and receivables. The cost overrun uses another $3 million.

These are illustrative sensitivities, not a fully integrated financial forecast. The real model would need to avoid double-counting and incorporate taxes, working capital, debt terms and cost flexibility.

But the lesson is straightforward: a company can be optimistic about growth and still need a conservative liquidity plan.

I would rather disappoint someone with a downside scenario in October than surprise the bank with one in April.

Valuation Should Change How We Think About Hurdle Rates

When market valuations are elevated, people sometimes argue that companies should simply raise every investment hurdle rate.

I wouldn’t make that leap automatically.

The appropriate required return depends on the project’s risk, cash flows and financing environment. A broad belief that stocks are overvalued doesn’t tell us the discount rate for a particular operating investment.

But market conditions can affect opportunity costs and the relative attractiveness of alternatives.

If the company can repurchase its own shares at a compelling discount to a reasonable intrinsic-value estimate, that is one potential use of capital. If shares appear expensive, the repurchase case weakens.

If acquisition prices rise, more deals may fail the return test. If debt financing becomes less attractive, marginal projects may no longer clear the hurdle.

I would update assumptions where the underlying economics changed, not move the hurdle rate because the headlines sound anxious.

The objective is disciplined capital allocation, not giving the discount rate a personality disorder.

Don’t Let the Market’s Multiple Set the Operating Strategy

A high valuation can create pressure to sustain an exceptional growth narrative.

Management may accelerate hiring, expand into adjacent markets or pursue acquisitions to support expectations. Some of those moves can be rational.

But I want to separate investments that create value from investments that merely make the growth story look exciting.

Suppose a new product is expected to generate $30 million in revenue over five years but requires $35 million in present-value costs. Unless there are credible additional benefits, that’s not a great investment simply because it makes the growth chart steeper.

I’d evaluate contribution, cash conversion, strategic options and risk-adjusted returns.

The market may reward a growth announcement in the short term. That doesn’t mean the underlying project earns its cost of capital.

I’ve seen too many plans where revenue gets the spotlight and returns are asked to wait backstage.

Eventually the cash flow arrives, or it doesn’t. The market has a way of noticing.

What About Private Companies?

Private companies don’t have a continuously quoted stock price, but the distinction between business quality and purchase price still matters.

Private-company leaders encounter valuation through acquisition offers, fundraising, ownership transitions, debt negotiations and comparable-company benchmarks.

A founder may reasonably believe the business will have its strongest year yet while rejecting an acquisition because the asking price assumes an even stronger future.

A private equity-backed CFO may need to reconcile a promising operating plan with a difficult exit valuation.

And a family-owned company may have no intention of selling but still need to evaluate whether a major investment beats alternative uses of cash.

I would not force public-market multiples onto a private company without considering size, liquidity, concentration, governance and other differences.

The same principle applies, though: estimate the cash the business can produce and evaluate the price or capital commitment separately.

A business doesn’t become more valuable merely because its owner has developed a close emotional relationship with the forecast.

How I’d Bring This to the Board

I would organize the discussion around three questions.

First, how strong is the operating plan? Show the drivers behind growth, margins, working capital and cash. Distinguish committed improvements from aspirations.

Second, what assumptions are embedded in the company’s valuation or financing options? Show reasonable ranges, not a single number pretending to be destiny.

Third, what capital decisions make sense under both the base case and a credible downside?

For each proposed investment, I’d include expected return, strategic rationale, cash requirements, downside exposure, timing and alternative uses of capital.

I’d also make clear which assumptions management controls and which depend on external markets.

That last distinction is important. A company can improve productivity. It cannot order investors to pay a 30-times earnings multiple forever.

The board should see a strong operating story and a disciplined capital story. They do not need to be identical.

In fact, a little tension between them may be evidence that Finance is doing its job.

A Practical Capital-Allocation Scorecard for 2027

I would give every material capital proposal the same basic scorecard.

Start with cash invested and timing. Then show expected incremental cash flows, risk-adjusted return, payback where useful, strategic value, downside liquidity effect and execution dependencies.

Add a comparison with the best realistic alternative. That might be debt reduction, a smaller investment, a different acquisition, a buyback or simply preserving flexibility.

Then identify the assumptions that would reverse the decision.

For an acquisition, it may be a lower synergy realization or slower growth. For a capacity expansion, weaker demand. For a buyback, a lower intrinsic-value range. For debt financing, reduced covenant headroom.

Finally, define who owns the post-investment review and when results will be checked.

This matters because companies are very good at approving investments and sometimes less enthusiastic about revisiting the original promise.

I would like the return calculation to remain in the room after the ribbon-cutting ceremony.

Optimism Can Be Rational. So Can Caution.

The Deloitte findings don’t tell me CFOs are confused. They tell me many finance leaders distinguish the prospects of businesses they know from the prices investors are paying across the market.

That is a useful distinction, especially when planning 2027.

The company may have a strong order book, improving productivity and attractive growth opportunities. It may also face expensive acquisition targets, demanding investor expectations and financing choices that require care.

I’d respond by making the operating forecast more evidence-based and the capital allocation process more disciplined.

I would not turn every market concern into an excuse to stop investing. A company that refuses every attractive project because stocks seem expensive may miss its best opportunities.

But I also wouldn’t let a confident outlook become permission to overpay for growth.

There is room for both ambition and skepticism. In Finance, I would argue we need both.

The CFO can believe in the business and still say no to the price.

That’s not inconsistency. That’s the job.

The Question I’d Ask Before the Next Big Check

Before approving a major acquisition, buyback or expansion, I’d ask one question: would we still like this decision if the market stopped applauding?

Would the investment generate acceptable cash returns without a higher valuation multiple? Would the acquisition make sense if the exit price were less generous? Would the business remain resilient if growth arrived later than planned?

If the answer is yes, we may have a genuinely attractive opportunity.

If the answer depends on investors remaining delighted indefinitely, I’d like to see another scenario.

Deloitte’s CFO survey captures an interesting moment: optimism about business prospects alongside widespread concern about stock valuations. I don’t think Finance needs to choose one feeling.

We need to understand what the business can deliver and what we’re being asked to pay.

A strong company deserves a strong plan. It doesn’t deserve an unlimited checkbook.

And if someone tells me a deal is too good to pass up because “the market loves this space,” I’m going to ask for the cash-flow model.

Preferably one that doesn’t require the market to stay in love forever.